详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]School of automation, Harbin University of Science and Technology, Harbin, Heilongjiang, 150080, China [2]CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China [3]Department of respiratory and critical care medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [4]School of Medical Informatics, China Medical University, Shenyang, Liaoning 110122, China [5]University of Chinese Academy of Sciences, Beijing, 100049, China

出处：

DOI：

ISSN：

摘要：

To predict epidermal growth factor receptor (EGFR) mutation status using quantitative radiomic biomarkers and representative clinical variables. The study included 180 patients diagnosed as of non-small cell lung cancer (NSCLC) with their pre-therapy computed tomography (CT) scans. Using a radiomic method, 485 features that reflect the heterogeneity and phenotype of tumors were extracted. Afterwards, these radiomic features were used for predicting epidermal growth factor receptor (EGFR) mutation status by a least absolute shrinkage and selection operator (LASSO) based on multivariable logistic regression. As a result, we found that radiomic features have prognostic ability in EGFR mutation status prediction. In addition, we used radiomic nomogram and calibration curve to test the performance of the model. Multivariate analysis revealed that the radiomic features had the potential to build a prediction model for EGFR mutation. The area under the receiver operating characteristic curve (AUC) for the training cohort was 0.8618, and the AUC for the validation cohort was 0.8725, which were superior to prediction model that used clinical variables alone. Radiomic features are better predictors of EGFR mutation status than conventional semantic CT image features or clinical variables to help doctors to decide who need EGFR tyrosine kinase inhibitor (TKI) treatment. Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]School of automation, Harbin University of Science and Technology, Harbin, Heilongjiang, 150080, China [2]CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China

共同第一作者：

通讯作者：

通讯机构： [2]CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China [3]Department of respiratory and critical care medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [5]University of Chinese Academy of Sciences, Beijing, 100049, China [*1]CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China. [*2]Department of respiratory and critical care medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：